Registration country:United States
A public company focused on regenerative medicine.
Company developing in vivo tissue augmentation/repair products. Reprogenesis merged in July 2000 with Creative Biomolecules and Ontogeny to form Curis, a public company focused on regenerative medicine. Curis is developing products that are designed to recreate the conditions that support the growth of cells and tissue.